A paediatric canopy system for aerosol administration and minimized environmental pollution

Acta Anaesthesiologica Scandinavica

Volumn 40, Issue 8 I, 1996, Pages 932-939

  Wahlin B ^a   Malmstrom B ^a   Soop, M ^a   Hellstrom L G ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

aerosol; canopy; infant; ribavirin; RSV infection

Indexed keywords

RIBAVIRIN;

AEROSOL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEVICE; HUMAN; INDOOR AIR POLLUTION; INFANT; INHALATIONAL DRUG ADMINISTRATION; PEDIATRIC SURGERY; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SAFETY;

EID: 0029841621     PISSN: 00015172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-6576.1996.tb04563.x     Document Type: Article

References (18)

1. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. AJDC 1986: 140: 543-546.
2. Hall CB, McBride JT, Walsh EE, Bell DM, Gala CL, Hildreth S et al. Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. N Engl J Med 1983: 308: 1443-1447.
3. Hall CB, McBride JT, Gala CL, Hidreth SW, Schnabel KC. Ribavirin treatment of respiratory syncytial viral infection in infants with underlying cardiopulmonary disease. JAMA 1985: 254: 3047-3051.
4. Smith DW, Fankel LR, Mathers LH, Tang ATS, Ariagno RL, Prober CG. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 1991: 325: 24-29.
5. Committee on Infectious Diseases, American Academy of Pediatrics. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 1993: 92: 501-504.
6. ICN Pharmaceuticals, Inc. Virazole (ribavirin) Product Monograph. March, 1993: 1-20.
7. Johnson EM. The effects of ribavirin on development and reproduction: a critical review of published and unpublished studies in experimental animals. J Am Coll Toxicol 1990: 9: 551-561.
8. Canadian Pediatric Society. Ribavirin: is there a risk for hospital personnel? Can Med Assoc J 1991: 144: 285-286.
9. Capsey LJ, Jones KL, Snell NJC. Safety and tolerance of nebulised ribavirin in clinical usage. Acta Ther 1992: 18: 133-147.
10. Deniers R. Update: Ribavirin administration during mechanical ventilation. Can J Respir Ther 1991: 27: 9-14.
11. Gladu JM, Ecobichon DJ. Evaluation of exposure of health care personnel to ribavirin. J Toxicol Environ Health 1989: 28: 1-12.
12. Torres A, Krilov LR, Jacobson JM, Kelly KJ, Havens PL. Reduced environmental exposure to aerosolized ribavirin using a simple containment system. Pediatr Infect Dis J 1991: 10: 217-221.
13. Byron PR, Phillips EM, Kuhn R. Ribavirin administration by inhalation: aerosol-generation factors controlling drug delivery to the lung. Respir Care 1988: 33: 1011-1019.
14. Knight V, Yu CP, Gilbert BE, Divine GW. Estimating the dosage of ribavirin aerosol according to age and other variables. J Infect Dis 1988: 158: 443-448.
15. Englund JA, Piedra PA, Ahn Y-M, Gilbert BE, Hiatt P. High-dose, short-duration ribavirin aerosol therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1994: 125: 635-641.
16. Arbetarskyddsstyrelsens Författnings Samling. Hygieniska gränsvärden AFS 1993: 5, AFS 1993: 9.
17. Hey EN, Katz G. The optimum thermal environment for naked babies. Arch Dis Child 1970: 45: 328-334.
18. Hey EN, O'Connell B. Oxygen consumption and heat balance in the cot-nursed baby. Arch Dis Child 1970: 45: 335-343.